White Paper: 5 Steps for Pharmaceutical Funding and Reimbursement in Canada and The Impacts of Covid-19
Published June 2022
Abstract:
The approval of a product for marketing by Health Canada does not imply that it will be financially sponsored by the government. The drug manufacturer must seek public drug program financing by submitting a comprehensive application per the ministry's established evidence-based drug funding assessment process.
This white paper looks at:
- Funding And Reimbursement for Special Access Drugs
- The Step-By-Step Funding and Reimbursement Process for Oncology and Non-Oncology Pharmaceuticals
- The Criteria Used by The Government to Determine Reimbursement
- The Impact of Covid-19 On Funding and Reimbursement
Keywords: drug reimbursement, pharmaceutical funding, special access drugs, food and drug regulations, non-cancer drugs, cancer drugs, COVID-19, pandemic, product development, NOC, DIN, orphan drug, Health Canada, CADTH, INESSS, CDEC, pERC, CSMEI, pCPA, PMPRB, CDR, pCODR
Click here to view White paper: Steps for Pharmaceutical Funding and Reimbursement in Canada and The Impacts of Covid-19